Why does quick-release bromocriptine decrease cardiac events?
Article first published online: 6 SEP 2011
© 2011 Blackwell Publishing Ltd
Diabetes, Obesity and Metabolism
Volume 13, Issue 10, pages 880–884, October 2011
How to Cite
Bell, D. S. H. (2011), Why does quick-release bromocriptine decrease cardiac events?. Diabetes, Obesity and Metabolism, 13: 880–884. doi: 10.1111/j.1463-1326.2011.01424.x
- Issue published online: 6 SEP 2011
- Article first published online: 6 SEP 2011
- Accepted manuscript online: 13 MAY 2011 12:56PM EST
- Date submitted 25 February 2011, date of first decision 29 April 2011, date of final acceptance 10 May 2011
- cardiovascular disease;
- diabetes complications;
- type 2 diabetes
A placebo-controlled prospective safety study of quick-release bromocriptine in patients with type 2 diabetes has shown a 40% reduction in cardiovascular events. Possible explanations for this decrease are that through re-establishing diurnal variation a decrease in insulin resistance and its associated risk factors occurs. In addition, a decrease in the activity of the sympathetic nervous and renin–angiotensin systems and re-establishment of diurnal variations in the pituitary–adrenal axis may play a role. However, the most probable explanation is that because of the lowering of insulin resistance there are decreases in hepatic glucose production and an increased uptake of glucose leading to decreased levels of postprandial glucose, free fatty acids and triglycerides, which cause decreases in inflammation, oxidative stress and accumulation of atheroma.